Spatiotemporally Controlled T-Cell Combination Therapy for Solid Tumor.

Area of Science:

• Oncology
• Immunotherapy
• Biotechnology

Background:

• Solid tumor complexity presents challenges for T-cell based therapies.
• Developing rational T-cell combinations and formulations remains difficult.

Purpose of the Study:

• To engineer a triple combination therapy using T cells, Indoleamine 2,3-dioxygenase inhibitors (IDOi), and Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i).
• To establish a spatiotemporally controlled T-cell engineering technology for formulating a single cell therapeutic combining these agents.

Main Methods:

• A sequentially responsive core-shell nanoparticle (SRN) encapsulating IDOi and CDK4/6i was developed and anchored onto T cells.
• SRN-T cells were designed for sequential drug release within the tumor microenvironment (TME).
• The technology leverages the acidic TME for initial IDOi release and intracellular glutathione (GSH) for subsequent CDK4/6i release.

Main Results:

• The engineered T cells successfully migrated into solid tumors.
• Sequential release of IDOi and CDK4/6i modulated the TME, restored tryptophan, activated effector T cells, inhibited Tregs, and upregulated CXCL10 and CCL5.
• This led to enhanced T-cell infiltration, significant tumor suppression, and prolonged survival in tumor-bearing mice.

Conclusions:

• The study demonstrates the efficacy of a tri-drug combination mediated by spatiotemporally controlled cell-engineering.
• This approach provides a rational and superior treatment strategy for solid tumors.
• The developed technology offers a novel therapeutic regimen for solid tumor treatment.